Category Archives: BioUtah News
Owlet Appoints Executive Jonathan Harris as New Company President and Chief Revenue Officer
LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, today announces the appointment of executive Jonathan Harris as its new President and Chief Revenue Officer. Harris joins Owlet at a pivotal time in its business – one month after receiving clearance from the U.S. Food and Drug […]
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers. This comprehensive model is expected to identify more patients that could benefit from a change in their breast care.
BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System
BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring, auto-identification, dose error reduction software and EMR interoperability BD Alaris™ Infusion System’s unique “One System” platform securely connects all patient modules to provide care teams […]
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally
Owlet Appoints Healthcare Executive Melissa Gonzales to Board of Directors
LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, is pleased to announce the addition of Melissa Gonzales to the Company’s Board of Directors. Gonzales brings more than 20 years of consumer and provider healthcare experience to Owlet, further advancing the Company as a leader in infant monitoring solutions. […]
Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program
The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform SALT LAKE CITY, July 13, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development […]
Co-Diagnostics, Inc. Announces Recent Grant Awards
The Company intends to use funds awarded by the Bill & Melinda Gates Foundation toward completion of tuberculosis and HPV tests for its Co-Dx PCR Home™ platform SALT LAKE CITY, July 18, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of […]
ELEVAR THERAPEUTICS ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMAB AS A FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
FORT LEE, NEW JERSEY, July 17, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. And a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the U.S. Food and Drug Administration (FDA) accepted a new drug application […]
Stuart Goldblatt Joins CenExel as CEO
Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July 17, 2023. Tom Wardle will transition to the role of Executive Chairman, CenExel Board of Directors. Said Tom Wardle, “We are very excited to have a […]
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today […]
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as […]
FDA Approves ARUP Laboratories’ AAV5 DetectCDx™, a First-Ever Companion Diagnostic Immunoassay for a Gene Therapy
SALT LAKE CITY—ARUP Laboratories today announced that the U.S. Food and Drug Administration (FDA) has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN™, a new gene therapy developed by BioMarin Pharmaceutical Inc., received contemporaneous FDA approval for the treatment of […]
